R. Bals (Marburg, Germany), J. T. Macfarlane (Nottingham, United Kingdom)
Community-acquired pneumonia Fine V: clinical profile and outcomes of ICU and non-ICU patients
M. A. Rivera, M. Cavalcanti, E. Garcia, M. A. Marcos, M. Valencia, J. Mensa, A. Torres (Barcelona, Spain)
|  |
Determinants of vaccination in patients with community acquired pneumonia (CAP) or chronic lung diseases
Y. Kohlhammer, M. Schwartz, T. Schaberg, H. Raspe, T. Schaefer (Luebeck, Rotenburg/Wuemme, Germany)
|  |
Hospitalisation costs for community-acquired pneumonia (CAP) in France (F), Germany (D), Japan (J) and USA
A. Neiss, D. Elkharrat, S. Kohno, J. A. Paladino, R. R. Reinert (Munich, Aachen, Germany; Paris, France; Nagasaki, Japan; Buffalo, United States Of America)
| |
Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila
J. Roig, M. Sabria, J. Alegre, M. Gurgui, J. C. Checa (Andorra, Andorra; Badalona, Barcelona, Madrid, Spain)
| |
Aetiology of lower respiratory tract infection (LRTI) in primary care
A. Holm, J. Nexøe, L. P. Nielsen, L. Bistrup, N. Obel, S. S. Pedersen, C. Pedersen (Odense, Denmark)
| |
Adenoviral delivery of elafin modulates lipopolysaccharide-induced leukocyte influx in the ovine lung both locally and distally
T. I. Brown, D. D. Collie, J. M. Sallenave (Edinburgh, United Kingdom)
| |
The antimicrobial molecule elafin protects the lung against Staphylococcus aureus infection
J. McMichael, A. Maxwell, K. Hayashi, K. Taylor, J. Dorin, J. M. Sallenave (Edinburgh, United Kingdom)
| |
Interleukin production by airway epithelial cells after h. influenzae exposure is not related to bacterial growth or passage
M. van Schilfgaarde, R. Lutter, P. van der Ley, F. Mooi, L. van Alphen (Bilthoven, Amsterdam, The Netherlands)
| |